The failing Fontan: etiology, diagnosis and management

References

• Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax26(3), 240–248 (1971).
   PubMed Web of Science ®Google Scholar
• Kreutzer G, Galindez E, Bono H, De Palma C, Laura JP. An operation for the correction of tricuspid atresia. J. Thorac. Cardiovasc. Surg.66(4), 613–621 (1973).
   PubMed Web of Science ®Google Scholar
• Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation96(5), 1507–1512 (1997).
   PubMed Web of Science ®Google Scholar
• Shaddy RE, Boucek MM, Hsu DT et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA298(10), 1171–1179 (2007).
   PubMed Web of Science ®Google Scholar
• Nagayama T, Hsu S, Zhang M et al. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J. Am. Coll. Cardiol.53(2), 207–215 (2009).
   PubMed Web of Science ®Google Scholar
• Hsu S, Nagayama T, Koitabashi N et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc. Res.81(2), 301–309 (2009).
   PubMed Web of Science ®Google Scholar
• Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ. Res.101(11), 1084–1095 (2007).
   PubMed Web of Science ®Google Scholar
• Kass DA. Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?. Circulation116(3), 233–235 (2007).
   PubMedGoogle Scholar
• Zhang M, Takimoto E, Hsu S et al. Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. J. Am. Coll. Cardiol.56(24), 2021–2030 (2011).
   Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5-inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry and clinical status in patients with stable systolic heart failure: results of a 1-year prospective, randomized, placebo-controlled study. Circ. Heart Fail.1, 8–17 (2010).
   Google Scholar
• Goldberg D, Szwasat A, Marino B et al. Abstract 2161: sildenafil improves ventricular performance in children and young adults after the Fontan operation. Circulation120(Suppl. 18), S603 (2009).
   Google Scholar
• Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J. Thorac. Cardiovasc. Surg.115(5), 1063–1073 (1998).
   PubMed Web of Science ®Google Scholar
• Feldt RH, Driscoll DJ, Offord KP et al. Protein-losing enteropathy after the Fontan operation. J. Thorac. Cardiovasc. Surg.112(3), 672–680 (1996).
   PubMed Web of Science ®Google Scholar
• Thorne SA, Hooper J, Kemp M, Somerville J. Gastro-intestinal protein loss in late survivors of Fontan surgery and other congenital heart disease. Eur. Heart J.19(3), 514–520 (1998).
   PubMed Web of Science ®Google Scholar
• Rychik J. Protein-losing enteropathy after Fontan operation. Congenit. Heart Dis.2(5), 288–300 (2007).
   PubMedGoogle Scholar
• Gewillig M. The Fontan circulation. Heart91(6), 839–846 (2005).
   PubMed Web of Science ®Google Scholar
• Gewillig M, Brown SC, Eyskens B et al. The Fontan circulation: who controls cardiac output?. Interact. Cardiovasc. Thorac. Surg.10(3), 428–433 (2010).
   PubMed Web of Science ®Google Scholar
• Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann. Thorac. Surg.82(2), 695–700 (2006).
   PubMed Web of Science ®Google Scholar
• Bode L, Eklund EA, Murch S, Freeze HH. Heparan sulfate depletion amplifies TNF-α-induced protein leakage in an in vitro model of protein-losing enteropathy. Am. J. Physiol. Gastrointest. Liver Physiol.288(5), G1015–G1023 (2005).
   PubMed Web of Science ®Google Scholar
• Bode L, Murch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J. Biol. Chem.281(12), 7809–7815 (2006).
   PubMed Web of Science ®Google Scholar
• Amadi B, Fagbemi AO, Kelly P et al. Reduced production of sulfated glycosaminoglycans occurs in Zambian children with Kwashiorkor but not marasmus. Am. J. Clin. Nutr.89(2), 592–600 (2009).
   PubMed Web of Science ®Google Scholar
• Rychik J. Management of protein-losing enteropathy after the Fontan procedure. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.1, 15–22 (1998).
   PubMedGoogle Scholar
• Rychik J, Spray TL. Strategies to treat protein-losing enteropathy. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.5, 3–11 (2002).
   PubMedGoogle Scholar
• Kelly AM, Feldt RH, Driscoll DJ, Danielson GK. Use of heparin in the treatment of protein-losing enteropathy after Fontan operation for complex congenital heart disease. Mayo Clin. Proc.73(8), 777–779 (1998).
   PubMed Web of Science ®Google Scholar
• Rychik J, Rome JJ, Jacobs ML. Late surgical fenestration for complications after the Fontan operation. Circulation96(1), 33–36 (1997).
   PubMedGoogle Scholar
• Rychik J, Piccoli DA, Barber G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am. J. Cardiol.68(8), 819–821 (1991).
   PubMed Web of Science ®Google Scholar
• Thacker D, Patel A, Dodds K, Goldberg DJ, Semeao E, Rychik J. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann. Thorac. Surg.89(3), 837–842 (2010).
   PubMed Web of Science ®Google Scholar
• Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J. Heart Lung Transplant.24(8), 1174–1176 (2005).
   PubMed Web of Science ®Google Scholar
• Costello JM, Steinhorn D, McColley S, Gerber ME, Kumar SP. Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics109(4), e67 (2002).
   Google Scholar
• Rychik J. Forty years of the Fontan operation: a failed strategy. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.13(1), 96–100 (2010).
   PubMedGoogle Scholar
• Paridon SM, Mitchell PD, Colan SD et al. A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J. Am. Coll. Cardiol.52(2), 99–107 (2008).
   PubMed Web of Science ®Google Scholar
• Giardini A, Hager A, Pace Napoleone C, Picchio FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann. Thorac. Surg.85(3), 818–821 (2008).
   PubMed Web of Science ®Google Scholar
• Giardini A, Specchia S, Tacy TA et al. Usefulness of cardiopulmonary exercise to predict long-term prognosis in adults with repaired tetralogy of Fallot. Am. J. Cardiol.99(10), 1462–1467 (2007).
   PubMed Web of Science ®Google Scholar
• Mitchell MB, Campbell DN, Ivy D et al. Evidence of pulmonary vascular disease after heart transplantation for Fontan circulation failure. J. Thorac. Cardiovasc. Surg.128(5), 693–702 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg DJ, French B, McBride MG et al. impact of oral sildenafil on exercise performance in children and young adults after Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation123(11), 1185–1193 (2011).
   PubMed Web of Science ®Google Scholar
• Cardarelli MG, Salim M, Love J et al. Berlin heart as a bridge to recovery for a failing Fontan. Ann. Thorac. Surg.87(3), 943–946 (2009).
   PubMed Web of Science ®Google Scholar
• Rodefeld MD, Boyd JH, Myers CD et al. Cavopulmonary assist: circulatory support for the univentricular Fontan circulation. Ann. Thorac. Surg.76(6), 1911–1916 (2003).
   PubMed Web of Science ®Google Scholar
• Riemer RK, Amir G, Reichenbach SH, Reinhartz O. Mechanical support of total cavopulmonary connection with an axial flow pump. J. Thorac. Cardiovasc. Surg.130(2), 351–354 (2005).
   PubMed Web of Science ®Google Scholar
• Myers CD, Mattix K, Presson RG Jr et al. Twenty-four hour cardiopulmonary stability in a model of assisted newborn Fontan circulation. Ann. Thorac. Surg.81(1), 264–270 (2006).
   PubMed Web of Science ®Google Scholar
• Lacour-Gayet FG, Lanning CJ, Stoica S et al. An artificial right ventricle for failing Fontan: in vitro and computational study. Ann. Thorac. Surg.88(1), 170–176 (2009).
   PubMed Web of Science ®Google Scholar
• Rodefeld MD, Coats B, Fisher T et al. Cavopulmonary assist for the univentricular Fontan circulation: von Karman viscous impeller pump. J. Thorac. Cardiovasc. Surg.140(3), 529–536 (2010).
   PubMed Web of Science ®Google Scholar
• Russo P, Wheeler A, Russo J, Tobias JD. Use of a ventricular assist device as a bridge to transplantation in a patient with single ventricle physiology and total cavopulmonary anastomosis. Paediatr. Anaesth.18(4), 320–324 (2008).
   PubMed Web of Science ®Google Scholar
• Pretre R, Haussler A, Bettex D, Genoni M. Right-sided univentricular cardiac assistance in a failing Fontan circulation. Ann. Thorac. Surg.86(3), 1018–1020 (2008).
   PubMed Web of Science ®Google Scholar
• Bernstein D, Naftel D, Chin C et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. Circulation114(4), 273–280 (2006).
   PubMedGoogle Scholar
• Lamour JM, Kanter KR, Naftel DC et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J. Am. Coll. Cardiol.54(2), 160–165 (2009).
   PubMed Web of Science ®Google Scholar
• Shaddy RE, Naftel DC, Kirklin JK et al. Outcome of cardiac transplantation in children. Survival in a contemporary multi-institutional experience. Pediatric Heart Transplant Study. Circulation94(Suppl. 9), II69–II73 (1996).
   PubMedGoogle Scholar
• Feingold B, Bowman P, Zeevi A et al. Survival in allosensitized children after listing for cardiac transplantation. J. Heart Lung Transplant.26(6), 565–571 (2007).
   PubMed Web of Science ®Google Scholar
• Griffiths ER, Kaza AK, Wyler von Ballmoos MC et al. Evaluating failing Fontans for heart transplantation: predictors of death. Ann. Thorac. Surg.88(2), 558–563 (2009).
   PubMed Web of Science ®Google Scholar